DHB (Dihydroboldenone)

A boldenone relative with no human clinical development — it briefly circulated as a "prohormone" in the 2000s and now exists only as an unapproved product.

DHB (1-testosterone, dihydroboldenone) is a structural relative of boldenone that cannot aromatise, so no oestrogen conversion occurs. It binds the androgen receptor and is described in community sources as strongly anabolic with a moderate androgenic profile. The honest framing is that almost everything said about its ratio and potency comes from historical animal bioassays or user report rather than human study — and animal potency ratios do not predict a human body-composition phenotype.

No human clinical program, period. Animal assay data from mid-century pharmacology plus modern community anecdote is the entire record — every claim about its profile is extrapolation.

• No therapeutic, performance or conventional clinical-safety trial of DHB was found, and there is no approved product anywhere. Very small controlled human metabolism and excretion studies do exist — 1-testosterone has been administered to volunteers to characterise metabolites and urinary detection — so "no human data at all" would overstate it. Those studies establish nothing about efficacy or clinical safety.
• It circulated as a supplement ingredient before scheduling, often labelled a "prohormone" — which is pharmacologically wrong: 1-testosterone is itself an active anabolic steroid, not a precursor to one. Its precursors, such as 1-androstenediol, are separate compounds, and a randomised four-week study of one of those in 17 resistance-trained men reported body-composition and strength changes alongside adverse lipid, liver and kidney markers. That is precursor evidence, not DHB evidence.
• Injection-site pain is the effect most consistently described by users, and it has no controlled characterisation.
• Class-level anabolic steroid harms apply in full. No DHB-specific frequency, magnitude or comparative claim is supportable.

Circulates as injectable esters. It does not aromatise. Human pharmacokinetics have never been characterised — no half-life, bioavailability or clearance figure exists for people, and any number in circulation is extrapolation. No FDA-approved product exists; illicit product identity, sterility and composition are unverifiable.

Injection-site reactions are widely reported, with incidence unknown. Long-term profile is entirely uncharacterized, plus the assumed full AAS package: HPG-axis suppression, lipid and cardiovascular strain. An unstudied steroid with no approved manufacturer is two layers of unknown, and both are load-bearing.

• Class-level severe outcomes reported with anabolic steroids, which no compound here is exempt from: cardiac arrest, heart attack, thickened heart muscle, heart failure and stroke; serious liver injury; and mania, paranoia, psychosis, hostility, aggression, dependence and depression on withdrawal.
• Pregnancy and breastfeeding: androgens can cause fetal harm including virilisation of a female fetus. Avoid in both.
• Everyone, in the sense that there is no human evidence base of any kind to weigh against the class risks
• FDA also identifies pulmonary embolism, deep-vein thrombosis, kidney injury, infertility and testicular shrinkage among serious risks of anabolic steroid use
• Anyone with cardiovascular disease, prostate or male breast cancer
• Children and adolescents, where androgens can close growth plates prematurely
• Women, given virilisation risk, some of which does not reverse

• Interactions have not been characterised for this compound. Other androgen labels describe altered anticoagulant activity and altered glycaemic control, so disclose exposure to any treating clinician rather than assuming.
• Any other steroid, where suppression and cardiovascular effects compound.
• Tested sport, where it is prohibited.

• Tell any clinician you see that you are using it. This entry does not provide panels or thresholds, because nothing here has been characterised well enough to make them meaningful.
• Class-level severe outcomes reported with anabolic steroids apply: cardiac arrest, heart attack, thickened heart muscle, heart failure and stroke; serious liver injury; and mania, paranoia, psychosis, hostility, aggression, dependence and depression on withdrawal.
• Any leg swelling, chest pain, breathlessness, jaundice or dark urine is urgent assessment rather than something to track.
• Injection-site infection, given unverifiable sterility of illicit product.

Nothing specific to this compound is established, because nothing about it has been studied in people. Endocrine and fertility recovery after anabolic-steroid use generally is variable, can take months and can be incomplete, with no reliable individual prognosis. Anyone in a prolonged low-testosterone state after stopping needs medical assessment.

US: 1-testosterone is explicitly listed as a Schedule III anabolic steroid under the CSA.

• Supplementing With Which Form of Creatine (Hydrochloride or Monohydrate) Alongside Resistance Training Can Have More Impacts on Anabolic/Catabolic Hormones, Strength and Body Composition?Physiol Res · 2024
• Growth Hormone(s), Testosterone, Insulin-Like Growth Factors, and Cortisol: Roles and Integration for Cellular Development and Growth With ExerciseFront Endocrinol (Lausanne) · 2020
• ErratumNeuroendocrinology · 2026
• Testosterone concentrations and prescription patterns of 1% testosterone gel in transgender and gender diverse individualsTher Adv Endocrinol Metab · 2022
• Testim 1% testosterone gel for the treatment of male hypogonadismClin Ther · 2005
• Metabolic studies of 1-testosterone in horsesDrug Test Anal · 2013
• Testosterone therapy--what, when and to whom?Aging Male · 2004
• No effect of testosterone or sexual ornamentation on telomere dynamics: A case study and meta-analysesEcol Evol · 2024
• Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationshipJ Sex Med · 2013
• Effect of acute exercise on the dynamics of testosterone levels: a systematic review of randomized controlled trialsPeerJ · 2026
• The relationship between circulating testosterone and inflammatory cytokines in menAging Male · 2019
• Review of Testim gelExpert Opin Pharmacother · 2006